# Administrative Bulletin 24-19

**101 CMR 320.00: Rates for Clinical Laboratory Services**

Effective January 1, 2024

2024 CPT Code Updates

## Summary

In accordance with 101 CMR 320.01(4)(c), the Executive Office of Health and Human Services (EOHHS) is adding new service codes effective for dates of service on and after January 1, 2024. Below are the codes that have been added. The rates in this administrative bulletin will apply until EOHHS issues revised rates.

### Added Codes

| **Codes** | **Rate** | **Description** |
| --- | --- | --- |
| 81457 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability |
| 81458 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability |
| 81459 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements |
| 81462 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements |
| 81463 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability |
| 81464 | $0.00 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements |
| 81517 | $155.40 | Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years |
| 82166 | $34.06 | Anti-mullerian hormone (AMH) |
| 86041 | $16.23 | Acetylcholine receptor (AChR); binding antibody |
| 86042 | $16.23 | Acetylcholine receptor (AChR); blocking antibody |
| 86043 | $10.63 | Acetylcholine receptor (AChR); modulating antibody |
| 86366 | $16.23 | Muscle-specific kinase (MuSK) antibody |
| 87523 | $37.78 | Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed |

Facebok logo[MassHealth on Facebook](https://www.facebook.com/MassHealth1/) X logo (formerly Twitter)[MassHealth on X (Twitter)](https://www.twitter.com/MassHealth) YouTube logo 
[MassHealth on YouTube](https://www.youtube.com/channel/UC1QQ61nTN7LNKkhjrjnYOUg)